Voyager Therapeutics (NASDAQ:VYGR) Share Price Passes Above 50 Day Moving Average – Here’s Why

Posted by Stanley Muller on Aug 22nd, 2026

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.36 and traded as high as $3.40. Voyager Therapeutics shares last traded at $3.32, with a volume of 716,940 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on VYGR shares. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Finally, HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Check Out Our Latest Report on Voyager Therapeutics

Voyager Therapeutics Price Performance

The firm has a 50 day moving average of $3.36 and a 200-day moving average of $3.69. The stock has a market capitalization of $208.89 million, a P/E ratio of -1.88 and a beta of 1.31.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. The company had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. As a group, equities analysts expect that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of VYGR. Barclays PLC increased its holdings in Voyager Therapeutics by 2.5% in the 4th quarter. Barclays PLC now owns 162,112 shares of the company’s stock valued at $637,000 after buying an additional 4,003 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Voyager Therapeutics by 14.1% during the 1st quarter. Quantinno Capital Management LP now owns 35,703 shares of the company’s stock worth $138,000 after acquiring an additional 4,405 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Voyager Therapeutics by 1.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock valued at $1,191,000 after acquiring an additional 5,560 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Voyager Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after acquiring an additional 6,748 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Voyager Therapeutics by 11.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 68,830 shares of the company’s stock valued at $266,000 after acquiring an additional 7,055 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.